Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination
| Autor: | Walt Orenstein, Manisha Patel, Paul A Gastañaduy, Paul A. Rota, Lakshmi Panagiotakopoulos, James L. Goodson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Measles Vaccine Population Supplement Articles Disease Global Health World Health Organization Measles Rubella vaccine elimination rubella vaccine Environmental health eradication Humans measles Immunology and Allergy Medicine Disease Eradication education Disease burden education.field_of_study Immunization Programs business.industry Incidence Public health Infant medicine.disease MMR Vaccination AcademicSubjects/MED00290 Infectious Diseases Measles virus Population Surveillance mumps Measles vaccine business medicine.drug |
| Zdroj: | The Journal of Infectious Diseases |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/jiaa793 |
| Popis: | The global measles vaccination program has been extraordinarily successful in reducing measles-related disease and deaths worldwide. Eradication of measles is feasible because of several key attributes, including humans as the only reservoir for the virus, broad access to diagnostic tools that can rapidly detect measles-infectious persons, and availability of highly safe and effective measles-containing vaccines (MCVs). All 6 World Health Organization (WHO) regions have established measles elimination goals. Globally, during 2000–2018, measles incidence decreased by 66% (from 145 to 49 cases per million population) and deaths decreased by 73% (from 535 600 to 142 300), drastically reducing global disease burden. Routine immunization with MCV has been the cornerstone for the control and prevention of measles. Two doses of MCV are 97% effective in preventing measles, qualifying MCV as one of the most effective vaccines ever developed. Mild adverse events occur in |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|